ICD-10-PCS › X New Technology › XW Anatomical Regions › XW0 New Technology, Anatomical... › XW01X27
XW01X27
Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7
RetiredICD-10-PCS procedure code.
No longer in the code set. Submitting it will not be accepted for a current date of service.
Use instead:
- 3E01XGF Introduction of Other Enzymatic/Chemical Agent into Subcutaneous Tissue, External Approach stated for FY2026
What has happened to this code
Every change the publisher made, from 2022 to now.
- FY2022 Added to the code set Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7
-
FY2024
Description revised
Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7Introduction of Anacaulase-bcdb into Subcutaneous Tissue, External Approach, New Technology Group 7 - FY2027 Removed from the code set
What this code says
Each character is read in its own position, so the same letter means different things in different places. Definitions are CMS's own.
3. Root operation Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
5. Approach External
Procedures performed directly on the skin or mucous membrane and procedures performed indirectly by the application of external force through the skin or mucous membrane
6. Device / Substance / Technology Talquetamab Antineoplastic
For example
- TALVEY(tm)
Codes in the same group
| Code | Description | Status |
|---|---|---|
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 | Retired |
| XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0134C | Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 | Valid |
| XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 | Valid |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | Retired |
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | Valid |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |